Puma Bio down 12% after hours as Nerlynx sales growth decelerates

Puma Biotechnology (NASDAQ:PBYI) Q3 results:

Revenues: $56.4M (-9.9%); Nerlynx sales: $53.5M (+1.7%).

Net loss: ($16.9M) (-19.0%); non-GAAP net income: ($4.7M) (-171.2%); loss/share: ($0.44) (-18.9%); non-GAAP EPS: ($0.12) (-175.0%).

Cash flow ops (9 mo.): $20.8M (+166.7%).

Shares down 12% after hours.

Previously: Puma Biotechnology EPS beats by $0.33, misses on revenue (Nov. 6)

https://seekingalpha.com/news/3515910-puma-bio-12-percent-hours-nerlynx-sales-growth-decelerates